Gland Pharma Ltd.'s consolidated net profit fell 3% year-on-year in the fourth quarter of financial year 2025, missing analysts' estimates.
The drugmaker posted a bottom line of Rs 186 crore in the quarter ended March, according to an exchange filing on Tuesday. Analysts tracked by Bloomberg had a consensus estimate of Rs 233 crore.
Gland Pharma Q4 Highlights (Consolidated, YoY)
Revenue down 7.3% to Rs 1,425 crore versus Rs 1,537 crore (Bloomberg estimate: Rs 1,552 crore).
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Ebitda down 0.7% to Rs 347.4 crore versus Rs 350 crore (Bloomberg estimate: Rs 376 crore).
Margin expands to 24.4% versus 22.8% (Bloomberg estimate: 24.2%).
Net profit down 3.1% to Rs 186 crore versus Rs 192 crore (Bloomberg estimate: Rs 233 crore).
The company's board recommended a final dividend of Rs 18 per equity share of a face value of Re 1 each for 2024–25. The dividend, upon approval by the shareholders, will be paid within 30 days from the date of the annual general meeting.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
The record date to determine the shareholders eligible for the dividend payout for the financial year ended March 31 has been fixed as Aug. 14, according to an exchange filing.
Shares of Gland Pharma closed 1.35% higher at Rs 1,503.90 apiece on the NSE ahead of the results, compared to a 1.05% fall in the benchmark Nifty.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
